Alpha corifolitropin is the main component of the drug Elonva from the Schering-Plough laboratory.
Treatment with Elonva should be initiated under the supervision of a physician experienced in the treatment of fertility problems (pregnancy difficulties). It is available as a solution for injection at 100 mcg / 0. 5 ml and 150 mcg / 0. 5 ml (box with 1 full syringe and one needle)
- Controlled ovarian stimulation (OCE) for the development of multiple follicles and pregnancy in women participating in the Assisted Human Reproduction Technology (AHR) program.
The value of Alpha Corifolitropin (ELONVA) can range from 1,800 to 2,800 reais.
Elonva’s active coyfolitropin alfa is contraindicated in patients with hypersensitivity (allergy) to the active substance or one of the excipients of the product formula, patients with ovarian, breast, uterus, pituitary or pittalamo tumors, vaginal bleeding (non-menstrual). without a known and diagnosed cause, primary ovarian insufficiency, enlarged ovarian or ovarian cysts, a history of ovarian hyperstimulation syndrome (HEO), an earlier cycle of EOC that resulted in more than 30 follicles greater than or equal to 11 mm highlighted by ultrasound, an initial number of antral follicles greater than 20, fibrous tumors of the uterus incompatible with pregnancy, malformations of the reproductive organs incompatible with pregnancy.
This medicine is not suitable for pregnant women who suspect they are pregnant or breast-feeding.
The most commonly reported adverse events are ovarian hyperstimulation syndrome, pain, pelvic discomfort, headache (headache), nausea (malaise), fatigue (fatigue) and breast pain (including increased breast tenderness), among others.
The recommended dose for women with a body weight greater than or equal to 60 kg is 100 mcg in a single injection and for women over 60 kg, the recommended dose is 150 mcg, in a single injection.
Elonva (alphacorifolitropin) should be given in a single subcutaneous injection, preferably in the abdominal wall, during the initial follicular phase of the menstrual cycle.
Elonva (alphacorifolitropin) is intended exclusively for a single subcutaneous injection. No additional injections of Elonva (alphacorifolitropin) should be performed during the same treatment cycle.
The injection should be given by a healthcare professional (e. g. a nurse), the patient himself or his partner, provided the doctor informs you.